Stockreport

Ultragenyx Announces Positive Topline Data from Ongoing Long-Term Extension Study of UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF Reductions in Major Clinical Events SustainedAfter an Additional 78 Weeks of UX007 Treatment Additional 20 Patients Naïve to UX007 Also Demonstrated Meaningful Reducti [Read more]